Can someone with a history of localized amyloidosis in the nasopharynx donate a kidney?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Kidney Donation with Localized Nasopharyngeal Amyloidosis

A person with localized nasopharyngeal amyloidosis who has shown no clinical signs of systemic disease for 6 years can likely donate a kidney, as localized amyloidosis does not pose the same risks as systemic forms of the disease.

Understanding Amyloidosis Types and Kidney Implications

  • Amyloidosis is classified into different types based on the precursor protein that forms amyloid fibrils, with AL (light chain) and ATTR (transthyretin) being the most common systemic forms 1
  • Localized amyloidosis differs fundamentally from systemic forms, as it remains confined to a specific tissue or organ without evidence of systemic involvement 2, 3
  • In systemic AL amyloidosis, the kidney is one of the most common sites of amyloid deposition, affecting approximately 70% of patients, typically presenting with nephrotic syndrome and progressive kidney dysfunction 1
  • Localized nasopharyngeal amyloidosis is a rare condition that typically presents with nasal obstruction, epistaxis, or hearing impairment, without systemic manifestations 2, 3

Evaluation for Kidney Donation in This Context

  • The absence of clinical signs of systemic disease over a 6-year period strongly suggests true localized amyloidosis rather than an early manifestation of systemic disease 4, 5
  • For living kidney donors with any history of amyloidosis, comprehensive evaluation should include:
    • Confirmation that the amyloidosis is truly localized through thorough clinical assessment 1
    • Screening for proteinuria and assessment of kidney function using cystatin C-based GFR measurements (more accurate than creatinine-based methods in patients with potential amyloidosis) 1
    • Evaluation for any signs of cardiac involvement, which would be concerning for systemic disease 1

Risk Assessment and Recommendations

  • The primary concern with systemic amyloidosis is the risk of recurrence in transplanted organs, which is not applicable in cases of truly localized disease 1
  • Unlike hereditary forms of amyloidosis (such as hereditary ATTR), localized nasopharyngeal amyloidosis is not genetically transmitted and does not pose a risk to donated organs 1, 4
  • The 6-year disease-free period without systemic manifestations provides strong evidence that the condition is truly localized and stable 2, 3
  • Kidney donation evaluation should follow standard protocols for living donors, with special attention to ruling out subclinical kidney involvement through sensitive testing for proteinuria 1

Potential Concerns and Monitoring

  • While rare, there is a theoretical possibility that localized amyloidosis could progress to systemic disease over time, though this is unlikely after 6 years of stability 4, 5
  • The donor should be informed about this theoretical risk and the importance of regular follow-up after donation 1
  • Post-donation monitoring should include periodic assessment for proteinuria and kidney function, which would be standard for any kidney donor 1

Conclusion

Based on current evidence, a history of localized nasopharyngeal amyloidosis with no signs of systemic involvement for 6 years should not preclude kidney donation. The evaluation should focus on confirming the absence of subclinical kidney involvement and ensuring adequate kidney function for donation 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Primary localized nasopharyngeal amyloidosis. A case report.

International journal of pediatric otorhinolaryngology, 1996

Research

Al amyloidosis.

Orphanet journal of rare diseases, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.